Median Technologies
About Median Technologies
Median Technologies is a pioneering healthcare AI company that leverages artificial intelligence, computer vision, and signal processing technologies to develop innovative imaging tests and services. Their core mission is to transform medical images into actionable insights to improve the diagnosis, treatment, and monitoring of patients, particularly in oncology. They aim to address life-threatening unmet medical needs by enabling earlier diagnosis and more effective treatment strategies.
For physicians, Median Technologies offers two primary solutions: iCRO and eyonis®. The iCRO (Imaging Contract Research Organization) business unit provides advanced imaging services and AI-powered image analysis for oncology clinical trials. This helps biopharmaceutical companies accelerate drug development by validating drug candidates’ mechanisms of action, discovering predictive imaging biomarkers, selecting appropriate patients for clinical trials, and monitoring disease progression. The eyonis® platform is a suite of AI-powered Software as a Medical Device (SaMD) designed for early cancer diagnosis. Notably, eyonis® LCS has received FDA 510(k) clearance in the United States and CE marking in Europe for lung cancer screening, enabling earlier detection of lung cancer when it is often curable. Median Technologies is also developing additional SaMD within the eyonis® portfolio for incidental pulmonary nodules (IPN) and hepatocellular carcinoma (HCC).
Focus Areas
Business Intelligence
| Key Investors | Katarina Martinson AB, Venture S.a.r.l, Nordica Life (Bermuda) Ltd, Lion Point Capital, Celestial Successor Fund, Matignon Finance, Inner Mongolia Furui Medical Science Co., Ltd., Canon Inc., Abingworth LLP, OFI Invest Asset Management SA, European Investment Bank, IRIS Capital Investment, New Enterprise Associates, Omega Funds |
| Partnerships | Tempus AI (for integration of eyonis® LCS into Tempus Pixel platform) |
| Acquisitions | unknown |
| Technology | Cloud-native, AI-powered imaging platform (eyonis®) leveraging proprietary artificial intelligence, computer vision, and signal processing technologies for imaging biomarker phenotyping and Software as Medical Devices (SaMD). |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Median Technologies offers AI-powered tools like eyonisu00ae that can enhance diagnostic accuracy and enable earlier detection of cancers such as lung and liver cancer, potentially leading to more effective treatment at earlier stages. Their solutions are designed to integrate into clinical workflows, providing actionable insights from medical images. The FDA clearance for eyonisu00ae LCS demonstrates a validated tool for lung cancer screening programs. Additionally, their involvement in oncology clinical trials means they are at the forefront of identifying new drug efficacies and predictive biomarkers, which could translate to improved patient selection and personalized treatment strategies in the future.
Median Technologies leverages a technology stack that includes Google Cloud for infrastructure, and they have collaborated with Medidata to streamline medical imaging in cancer clinical trials. They also have a non-exclusive distribution agreement with Tempus AI to integrate eyonisu00ae LCS into the Tempus Pixel platform, expanding access to their lung cancer screening device within clinical workflows. Their internal data collection for retrospective studies and algorithm validation utilizes Datacapt eCRF, ensuring secure, compliant, and flexible data centralization. These integrations highlight their commitment to interoperability and leveraging established platforms for broader reach and efficiency.
What the Web Says
Median Technologies is a French health technology company specializing in AI-driven medical imaging products and services for cancer diagnosis and treatment. They have two main platforms: iSee for imaging services in clinical trials and eyonis for non-invasive diagnostic tests. The company has recently achieved FDA clearance and CE marking for its eyonisu00ae LCS product, indicating significant progress in regulatory approvals and commercialization efforts. While there's a strong belief in the company's potential, particularly with its innovative AI solutions for oncology, some employee reviews highlight areas for improvement in internal communication and work-life balance.
Overall: MixedStrengths
- Pioneering AI for early cancer diagnosis and treatment.
- Strong regulatory progress with FDA clearance and CE marking for eyonisu00ae LCS.
- Addresses a massive unmet need in lung cancer screening.
- Offers best-in-class central imaging solutions for oncology clinical trials.
- Supportive staff and a sense of mission (according to some employees).
- Good work environment and culture (according to some employees).
Limitations
- Work-life balance can be unbalanced.
- Lack of communication and poor management.
- Job security and advancement are concerns for some employees.
- Fast-growing company, potentially growing too fast.
- Potential for slow adoption by radiologists and hospitals due to IT integration challenges and political budgets.
- Competition in the AI + radiology space from bigger, better-capitalized players.
Based on reviews from: Indeed.com, Reddit, Median Technologies (medtech.ai), Medidata Solutions, BioSpace, PitchBook
Last updated: 2026-09-10
Videos
News, demos, and interviews about Median Technologies.
Videos load interactively. If none appear, search YouTube for Median Technologies →
Press & Coverage
Frequently Asked Questions
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]